These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

229 related items for PubMed ID: 19817747

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Gleason score 7 screen-detected prostate cancers initially managed expectantly: outcomes in 50 men.
    van den Bergh RC, Roemeling S, Roobol MJ, Aus G, Hugosson J, Rannikko AS, Tammela TL, Bangma CH, Schröder FH.
    BJU Int; 2009 Jun; 103(11):1472-7. PubMed ID: 19154509
    [Abstract] [Full Text] [Related]

  • 3. Active surveillance for the management of prostate cancer in a contemporary cohort.
    Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR.
    Cancer; 2008 Jun 15; 112(12):2664-70. PubMed ID: 18433013
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience.
    Soloway MS, Soloway CT, Williams S, Ayyathurai R, Kava B, Manoharan M.
    BJU Int; 2008 Jan 15; 101(2):165-9. PubMed ID: 17850361
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M, Zhu X, Rannikko A, Staerman F, Valdagni R, Pickles T, Bangma CH, Roobol MJ.
    Eur Urol; 2012 Aug 15; 62(2):195-200. PubMed ID: 22342775
    [Abstract] [Full Text] [Related]

  • 9. Early outcomes of active surveillance for localized prostate cancer.
    Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D.
    BJU Int; 2005 May 15; 95(7):956-60. PubMed ID: 15839912
    [Abstract] [Full Text] [Related]

  • 10. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
    Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.
    Int J Radiat Oncol Biol Phys; 2005 Nov 01; 63(3):795-9. PubMed ID: 15925452
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Active surveillance for low-risk prostate cancer worldwide: the PRIAS study.
    Bul M, Zhu X, Valdagni R, Pickles T, Kakehi Y, Rannikko A, Bjartell A, van der Schoot DK, Cornel EB, Conti GN, Boevé ER, Staerman F, Vis-Maters JJ, Vergunst H, Jaspars JJ, Strölin P, van Muilekom E, Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2013 Apr 01; 63(4):597-603. PubMed ID: 23159452
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Apr 01; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 15. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G, Salomon L, Xylinas E, Allory Y, Vordos D, Hoznek A, Abbou CC, de la Taille A.
    J Urol; 2010 Feb 01; 183(2):539-44. PubMed ID: 20006888
    [Abstract] [Full Text] [Related]

  • 16. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ, Aronson WJ, Terris MK, Kane CJ, Amling CL, Dorey F, Presti JC.
    Cancer; 2003 Dec 01; 98(11):2344-50. PubMed ID: 14635068
    [Abstract] [Full Text] [Related]

  • 17. Prostate-specific antigen velocity in untreated, localized prostate cancer.
    Venkitaraman R, Norman A, Woode-Amissah R, Dearnaley D, Horwich A, Huddart R, Parker C.
    BJU Int; 2008 Jan 01; 101(2):161-4. PubMed ID: 17850368
    [Abstract] [Full Text] [Related]

  • 18. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.
    Int J Radiat Oncol Biol Phys; 2004 Apr 01; 58(5):1520-9. PubMed ID: 15050332
    [Abstract] [Full Text] [Related]

  • 19. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
    D'Amico AV, Whittington R, Malkowicz SB, Cote K, Loffredo M, Schultz D, Chen MH, Tomaszewski JE, Renshaw AA, Wein A, Richie JP.
    Cancer; 2002 Jul 15; 95(2):281-6. PubMed ID: 12124827
    [Abstract] [Full Text] [Related]

  • 20. Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy.
    Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M, Shinohara K.
    BJU Int; 2009 Sep 15; 104(5):600-4. PubMed ID: 19245439
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.